Market Overview

Morgan Stanley Upgrades Intercept Pharma, Maintains $100 Target

Morgan Stanley Upgrades Intercept Pharma, Maintains $100 Target
  • Intercept Pharmaceuticals Inc (NASDAQ: ICPT) shares have declined 63.88 percent over the past six months, reaching a low of $99.32 on January 28.
  • Morgan Stanley’s Andrew S. Berens has upgraded the rating on the company from Underweight to Equal-Weight, with a price target of $100.
  • Although the stock is likely to remain significantly volatile until the FDA panel in April, Berens believes the share price already reflects the known risks.

Analyst Andrew Berens mentioned that Intercept Pharma’s share price had declined meaningfully since the announcement in August 2015 that the Phase 2 NASH study in Japan had failed and that there would be a delay of three months in the FDA decision regarding the use of obeticholic acid (OCA) for the treatment of primary biliary cholangitis (PBC).

“While we still have concerns about the clinical, regulatory, and commercial outlook for the OCA development program in both NASH and PBC, at current levels we believe ICPT shares reflect our anticipated risks ahead of the briefing documents to be released for the April 7 FDA advisory panel,” Berens explained.

Related Link: Maybe Some Good News For A Big Biotech ETF

Berens believes that the panel would not only discuss the risk/benefit of OCA in PBC, but also the validity of using a surrogate endpoint, a smaller than expected market opportunity and relevance of itching and lipid changes.

“Additionally, we anticipate discussions about potential off-label usage in NASH, where the agency may provide its first thoughts about the lipid homeostasis alterations with the drug,” the Morgan Stanley report said.

However, Berens also expressed optimism regarding the possibility of “an ultimate endorsement and approval in PBC.”

Image Credit: Public Domain

Latest Ratings for ICPT

Jan 2021B of A SecuritiesDowngradesNeutralUnderperform
Dec 2020JefferiesDowngradesBuyHold
Nov 2020Canaccord GenuityMaintainsHold

View More Analyst Ratings for ICPT
View the Latest Analyst Ratings


Related Articles (ICPT)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas Upgrades Health Care Price Target FDA Analyst Ratings

Latest Ratings

MRTXHC Wainwright & Co.Maintains257.0
NVDATruist SecuritiesMaintains672.0
BLKBMO CapitalMaintains715.0
BLKDeutsche BankMaintains838.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at